stockrowOramed Pharmaceuticals Inc.
ORMPOramed Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 49.3% from fiscal 2023.
- Revenue
- +193.3%
- EPS
- +493.8%
- Free cash flow
- +94.3%
Quarter to June 2026, against a year earlier
Follow ORMP
Alert me
Oramed Pharmaceuticals Inc. (ORMP) Return on invested capital
Oramed Pharmaceuticals Inc.'s return on invested capital over the twelve months to 30 June 2026 was −3.40%, up 9.4 percentage points from fiscal 2025 (−12.8%). Over the past ten years it has ranged from −1,302.7% (fiscal 2018) to 0.00% (fiscal 2022); the current reading is higher than 54% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −12.8% | 221.01 |
| FY2024 | −233.8% | 931.19 |
| FY2023 | −1,165.0% | (1,164.97) |
| FY2022 | 0.00% | 0.00 |
| FY2022 | 0.00% | 37.89 |
| FY2021 | −37.9% | 29.77 |
| FY2021 | −67.7% | (67.66) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 1,302.68 |
| FY2018 | −1,302.7% | (1,302.68) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| STRO Sutro Biopharma, Inc. compare | 0.00% |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | 0.00% |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.00% |
| WHWK Whitehawk Therapeutics, Inc. compare | 0.00% |
| ORMP Oramed Pharmaceuticals Inc. | −3.40% |
| CNTN Canton Strategic Holdings, Inc. compare | −8.11% |
| ALXO ALX Oncology Holdings Inc. compare | −673.3% |
| PEPG PepGen, Inc. compare | −2,076.3% |
| MDWD MediWound Ltd. compare | −6,551.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)